Search - tctmd.com

Displaying 61 - 80 of 174

Sort: Relevancy | Date

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

News Conference News ESC 2020

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

September 04, 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

News Conference News ESC 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

September 04, 2020

Implantation Technique Influences LV Remodeling After TMVR

News Conference News ESC 2020

Implantation Technique Influences LV Remodeling After TMVR

September 04, 2020

Got Mail? Letter-Based Intervention Doesn’t Boost OAC Initiation for A-fib

News Conference News ESC 2020

Got Mail? Letter-Based Intervention Doesn’t Boost OAC Initiation for A-fib

September 03, 2020

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

News Conference News ESC 2020

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

Michael O'Riordan

September 01, 2020

News Conference News ESC 2020

Dapagliflozin Wins in Patients With CKD

August 31, 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

August 31, 2020

Trimetazidine Safe but Not Protective Long-term After PCI

News Conference News ESC 2020

Trimetazidine Safe but Not Protective Long-term After PCI

August 30, 2020

News Conference News ESC 2020

Go With Aspirin Alone After TAVR When Anticoagulation Isn’t Needed: POPular TAVI

August 30, 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

September 10, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

Community-Level Salt-Swapping Strategy Pays Dividends in Peru

News Conference News ESC 2019

Community-Level Salt-Swapping Strategy Pays Dividends in Peru

September 09, 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

September 06, 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31997-X/fulltext

News Conference News ESC 2019

Ten-Year SYNTAXES Results Fix Roles for CABG, PCI in Complex CAD

September 05, 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.